SuperSonic Imagine: Sales Growth in Q1 2015: +11% to €3.2 Million

Regulatory News:

SuperSonic Imagine (Paris:SSI) (Euronext: SSI, FR0010526814, PEA-PME eligible), a company specialized in ultrasound medical imaging, today announces its revenue for the first quarter of 2015.

Unaudited data
Note (*): these activities are not part of the Group’s core business and the associated revenue will not occur regularly.

Supersonic Imagine’s sales for the 1^st quarter of 2015 were €3.2 million which represents a growth of 11% compared to March 31, 2014, mainly driven by Asia and the Americas. At constant currency, sales increased by 2% between the same periods. Sales of products and services totaled €2.9 million and €371 thousand respectively, thus accounting for 89% and 11% of total sales over the period.

After inclusion of Other revenue, SuperSonic Imagine’s total revenue for Q1 2015 was €3.4 million.

Tom Egelund, CEO of SuperSonic Imagine, concludes: "The growth rate over this first quarter, which traditionally has the lowest impact on our annual sales results, does not reflect our ambitious goals for this year. The investments we have recently made to improve our sales structure, notably in the USA and Japan, have not yet had time to deliver full benefits and we are continuing to increase our direct sales force in our key markets as well as expanding our distribution network”.

Next press release: 1H sales, on July 21^st 2015

Annual General Shareholder meeting: May 29^th, 2015

About SuperSonic Imagine

Founded in 2005 and based in Aix-en-Provence (France), SuperSonic Imagine is a company specializing in medical imaging. The company designs, develops and markets a revolutionary ultrasound system, Aixplorer^®, with an UltraFast™ platform that can acquire images 200 times faster than conventional ultrasound systems. Aixplorer^® is the only system that can image two types of waves: ultrasound waves ensure excellent image quality and shear waves, which allow physicians to visualize and analyze the stiffness of tissue in a real-time, reliable, reproducible and non-invasive manner. This innovation, ShearWave™ Elastography, significantly improves the detection and characterization of numerous pathologies in several applications including breast, thyroid, liver and prostate. SuperSonic Imagine has been granted regulatory clearances for the commercialization of Aixplorer^® in the main global markets. Over the past years, SuperSonic Imagine enjoyed the backing of several prestigious investors, among which Auriga Partners, Edmond de Rothschild Investment Partners, Bpifrance, Omnes Capital and NBGI.

For more information about SuperSonic Imagine, please go to www.supersonicimagine.com